Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis
<i<Background and Objectives</i<: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of dis...
Ausführliche Beschreibung
Autor*in: |
Miriam Fedičová [verfasserIn] Pavol Mikula [verfasserIn] Zuzana Gdovinová [verfasserIn] Marianna Vitková [verfasserIn] Norbert Žilka [verfasserIn] Jozef Hanes [verfasserIn] Lýdia Frigová [verfasserIn] Jarmila Szilasiová [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2023 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Medicina - MDPI AG, 2016, 59(2023), 5, p 865 |
---|---|
Übergeordnetes Werk: |
volume:59 ; year:2023 ; number:5, p 865 |
Links: |
Link aufrufen |
---|
DOI / URN: |
10.3390/medicina59050865 |
---|
Katalog-ID: |
DOAJ094343918 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ094343918 | ||
003 | DE-627 | ||
005 | 20240413033508.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240413s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/medicina59050865 |2 doi | |
035 | |a (DE-627)DOAJ094343918 | ||
035 | |a (DE-599)DOAJaf300faefd1541669aed63075b4289cb | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a R5-920 | |
100 | 0 | |a Miriam Fedičová |e verfasserin |4 aut | |
245 | 1 | 0 | |a Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a <i<Background and Objectives</i<: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of disease activity (NEDA) in a cohort of multiple sclerosis (MS) patients. <i<Materials and Methods:</i< Levels of pNfL (SIMOA) were examined in 141 MS patients and analyzed in relationship to the NEDA-3 status (absence of relapse, disability worsening, and MRI activity) and NEDA-4 (NEDA-3 extended by brain volume loss ≤ 0.4%) during the last 12 months. Patients were divided into two groups: annual pNfL change with an increase of less than 10% (group 1), and pNfL increases of more than 10% (group 2). <i<Results:</i< The mean age of the study participants (<i<n</i< = 141, 61% females) was 42.33 years (SD, 10.17), and the median disability score was 4.0 (3.5–5.0). The ROC analysis showed that a pNfL annual change ≥ 10% correlates with the absence of the NEDA-3 status (<i<p</i< < 0.001; AUC: 0.92), and the absence of the NEDA-4 status (<i<p</i< < 0.001; AUC: 0.839). <i<Conclusions:</i< Annual plasma NfL increases of more than 10% appear to be a useful tool for assessing disease activity in treated MS patients. | ||
650 | 4 | |a multiple sclerosis | |
650 | 4 | |a disease activity | |
650 | 4 | |a neurofilament light chain | |
650 | 4 | |a neurofilament dynamics | |
650 | 4 | |a NEDA | |
653 | 0 | |a Medicine (General) | |
700 | 0 | |a Pavol Mikula |e verfasserin |4 aut | |
700 | 0 | |a Zuzana Gdovinová |e verfasserin |4 aut | |
700 | 0 | |a Marianna Vitková |e verfasserin |4 aut | |
700 | 0 | |a Norbert Žilka |e verfasserin |4 aut | |
700 | 0 | |a Jozef Hanes |e verfasserin |4 aut | |
700 | 0 | |a Lýdia Frigová |e verfasserin |4 aut | |
700 | 0 | |a Jarmila Szilasiová |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Medicina |d MDPI AG, 2016 |g 59(2023), 5, p 865 |w (DE-627)354543296 |w (DE-600)2088820-X |x 16489144 |7 nnns |
773 | 1 | 8 | |g volume:59 |g year:2023 |g number:5, p 865 |
856 | 4 | 0 | |u https://doi.org/10.3390/medicina59050865 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/af300faefd1541669aed63075b4289cb |z kostenfrei |
856 | 4 | 0 | |u https://www.mdpi.com/1648-9144/59/5/865 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1010-660X |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1648-9144 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 59 |j 2023 |e 5, p 865 |
author_variant |
m f mf p m pm z g zg m v mv n ž nž j h jh l f lf j s js |
---|---|
matchkey_str |
article:16489144:2023----::nullsaerflmndnmciaestvboakrfiesatvtip |
hierarchy_sort_str |
2023 |
callnumber-subject-code |
R |
publishDate |
2023 |
allfields |
10.3390/medicina59050865 doi (DE-627)DOAJ094343918 (DE-599)DOAJaf300faefd1541669aed63075b4289cb DE-627 ger DE-627 rakwb eng R5-920 Miriam Fedičová verfasserin aut Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <i<Background and Objectives</i<: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of disease activity (NEDA) in a cohort of multiple sclerosis (MS) patients. <i<Materials and Methods:</i< Levels of pNfL (SIMOA) were examined in 141 MS patients and analyzed in relationship to the NEDA-3 status (absence of relapse, disability worsening, and MRI activity) and NEDA-4 (NEDA-3 extended by brain volume loss ≤ 0.4%) during the last 12 months. Patients were divided into two groups: annual pNfL change with an increase of less than 10% (group 1), and pNfL increases of more than 10% (group 2). <i<Results:</i< The mean age of the study participants (<i<n</i< = 141, 61% females) was 42.33 years (SD, 10.17), and the median disability score was 4.0 (3.5–5.0). The ROC analysis showed that a pNfL annual change ≥ 10% correlates with the absence of the NEDA-3 status (<i<p</i< < 0.001; AUC: 0.92), and the absence of the NEDA-4 status (<i<p</i< < 0.001; AUC: 0.839). <i<Conclusions:</i< Annual plasma NfL increases of more than 10% appear to be a useful tool for assessing disease activity in treated MS patients. multiple sclerosis disease activity neurofilament light chain neurofilament dynamics NEDA Medicine (General) Pavol Mikula verfasserin aut Zuzana Gdovinová verfasserin aut Marianna Vitková verfasserin aut Norbert Žilka verfasserin aut Jozef Hanes verfasserin aut Lýdia Frigová verfasserin aut Jarmila Szilasiová verfasserin aut In Medicina MDPI AG, 2016 59(2023), 5, p 865 (DE-627)354543296 (DE-600)2088820-X 16489144 nnns volume:59 year:2023 number:5, p 865 https://doi.org/10.3390/medicina59050865 kostenfrei https://doaj.org/article/af300faefd1541669aed63075b4289cb kostenfrei https://www.mdpi.com/1648-9144/59/5/865 kostenfrei https://doaj.org/toc/1010-660X Journal toc kostenfrei https://doaj.org/toc/1648-9144 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 59 2023 5, p 865 |
spelling |
10.3390/medicina59050865 doi (DE-627)DOAJ094343918 (DE-599)DOAJaf300faefd1541669aed63075b4289cb DE-627 ger DE-627 rakwb eng R5-920 Miriam Fedičová verfasserin aut Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <i<Background and Objectives</i<: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of disease activity (NEDA) in a cohort of multiple sclerosis (MS) patients. <i<Materials and Methods:</i< Levels of pNfL (SIMOA) were examined in 141 MS patients and analyzed in relationship to the NEDA-3 status (absence of relapse, disability worsening, and MRI activity) and NEDA-4 (NEDA-3 extended by brain volume loss ≤ 0.4%) during the last 12 months. Patients were divided into two groups: annual pNfL change with an increase of less than 10% (group 1), and pNfL increases of more than 10% (group 2). <i<Results:</i< The mean age of the study participants (<i<n</i< = 141, 61% females) was 42.33 years (SD, 10.17), and the median disability score was 4.0 (3.5–5.0). The ROC analysis showed that a pNfL annual change ≥ 10% correlates with the absence of the NEDA-3 status (<i<p</i< < 0.001; AUC: 0.92), and the absence of the NEDA-4 status (<i<p</i< < 0.001; AUC: 0.839). <i<Conclusions:</i< Annual plasma NfL increases of more than 10% appear to be a useful tool for assessing disease activity in treated MS patients. multiple sclerosis disease activity neurofilament light chain neurofilament dynamics NEDA Medicine (General) Pavol Mikula verfasserin aut Zuzana Gdovinová verfasserin aut Marianna Vitková verfasserin aut Norbert Žilka verfasserin aut Jozef Hanes verfasserin aut Lýdia Frigová verfasserin aut Jarmila Szilasiová verfasserin aut In Medicina MDPI AG, 2016 59(2023), 5, p 865 (DE-627)354543296 (DE-600)2088820-X 16489144 nnns volume:59 year:2023 number:5, p 865 https://doi.org/10.3390/medicina59050865 kostenfrei https://doaj.org/article/af300faefd1541669aed63075b4289cb kostenfrei https://www.mdpi.com/1648-9144/59/5/865 kostenfrei https://doaj.org/toc/1010-660X Journal toc kostenfrei https://doaj.org/toc/1648-9144 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 59 2023 5, p 865 |
allfields_unstemmed |
10.3390/medicina59050865 doi (DE-627)DOAJ094343918 (DE-599)DOAJaf300faefd1541669aed63075b4289cb DE-627 ger DE-627 rakwb eng R5-920 Miriam Fedičová verfasserin aut Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <i<Background and Objectives</i<: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of disease activity (NEDA) in a cohort of multiple sclerosis (MS) patients. <i<Materials and Methods:</i< Levels of pNfL (SIMOA) were examined in 141 MS patients and analyzed in relationship to the NEDA-3 status (absence of relapse, disability worsening, and MRI activity) and NEDA-4 (NEDA-3 extended by brain volume loss ≤ 0.4%) during the last 12 months. Patients were divided into two groups: annual pNfL change with an increase of less than 10% (group 1), and pNfL increases of more than 10% (group 2). <i<Results:</i< The mean age of the study participants (<i<n</i< = 141, 61% females) was 42.33 years (SD, 10.17), and the median disability score was 4.0 (3.5–5.0). The ROC analysis showed that a pNfL annual change ≥ 10% correlates with the absence of the NEDA-3 status (<i<p</i< < 0.001; AUC: 0.92), and the absence of the NEDA-4 status (<i<p</i< < 0.001; AUC: 0.839). <i<Conclusions:</i< Annual plasma NfL increases of more than 10% appear to be a useful tool for assessing disease activity in treated MS patients. multiple sclerosis disease activity neurofilament light chain neurofilament dynamics NEDA Medicine (General) Pavol Mikula verfasserin aut Zuzana Gdovinová verfasserin aut Marianna Vitková verfasserin aut Norbert Žilka verfasserin aut Jozef Hanes verfasserin aut Lýdia Frigová verfasserin aut Jarmila Szilasiová verfasserin aut In Medicina MDPI AG, 2016 59(2023), 5, p 865 (DE-627)354543296 (DE-600)2088820-X 16489144 nnns volume:59 year:2023 number:5, p 865 https://doi.org/10.3390/medicina59050865 kostenfrei https://doaj.org/article/af300faefd1541669aed63075b4289cb kostenfrei https://www.mdpi.com/1648-9144/59/5/865 kostenfrei https://doaj.org/toc/1010-660X Journal toc kostenfrei https://doaj.org/toc/1648-9144 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 59 2023 5, p 865 |
allfieldsGer |
10.3390/medicina59050865 doi (DE-627)DOAJ094343918 (DE-599)DOAJaf300faefd1541669aed63075b4289cb DE-627 ger DE-627 rakwb eng R5-920 Miriam Fedičová verfasserin aut Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <i<Background and Objectives</i<: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of disease activity (NEDA) in a cohort of multiple sclerosis (MS) patients. <i<Materials and Methods:</i< Levels of pNfL (SIMOA) were examined in 141 MS patients and analyzed in relationship to the NEDA-3 status (absence of relapse, disability worsening, and MRI activity) and NEDA-4 (NEDA-3 extended by brain volume loss ≤ 0.4%) during the last 12 months. Patients were divided into two groups: annual pNfL change with an increase of less than 10% (group 1), and pNfL increases of more than 10% (group 2). <i<Results:</i< The mean age of the study participants (<i<n</i< = 141, 61% females) was 42.33 years (SD, 10.17), and the median disability score was 4.0 (3.5–5.0). The ROC analysis showed that a pNfL annual change ≥ 10% correlates with the absence of the NEDA-3 status (<i<p</i< < 0.001; AUC: 0.92), and the absence of the NEDA-4 status (<i<p</i< < 0.001; AUC: 0.839). <i<Conclusions:</i< Annual plasma NfL increases of more than 10% appear to be a useful tool for assessing disease activity in treated MS patients. multiple sclerosis disease activity neurofilament light chain neurofilament dynamics NEDA Medicine (General) Pavol Mikula verfasserin aut Zuzana Gdovinová verfasserin aut Marianna Vitková verfasserin aut Norbert Žilka verfasserin aut Jozef Hanes verfasserin aut Lýdia Frigová verfasserin aut Jarmila Szilasiová verfasserin aut In Medicina MDPI AG, 2016 59(2023), 5, p 865 (DE-627)354543296 (DE-600)2088820-X 16489144 nnns volume:59 year:2023 number:5, p 865 https://doi.org/10.3390/medicina59050865 kostenfrei https://doaj.org/article/af300faefd1541669aed63075b4289cb kostenfrei https://www.mdpi.com/1648-9144/59/5/865 kostenfrei https://doaj.org/toc/1010-660X Journal toc kostenfrei https://doaj.org/toc/1648-9144 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 59 2023 5, p 865 |
allfieldsSound |
10.3390/medicina59050865 doi (DE-627)DOAJ094343918 (DE-599)DOAJaf300faefd1541669aed63075b4289cb DE-627 ger DE-627 rakwb eng R5-920 Miriam Fedičová verfasserin aut Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <i<Background and Objectives</i<: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of disease activity (NEDA) in a cohort of multiple sclerosis (MS) patients. <i<Materials and Methods:</i< Levels of pNfL (SIMOA) were examined in 141 MS patients and analyzed in relationship to the NEDA-3 status (absence of relapse, disability worsening, and MRI activity) and NEDA-4 (NEDA-3 extended by brain volume loss ≤ 0.4%) during the last 12 months. Patients were divided into two groups: annual pNfL change with an increase of less than 10% (group 1), and pNfL increases of more than 10% (group 2). <i<Results:</i< The mean age of the study participants (<i<n</i< = 141, 61% females) was 42.33 years (SD, 10.17), and the median disability score was 4.0 (3.5–5.0). The ROC analysis showed that a pNfL annual change ≥ 10% correlates with the absence of the NEDA-3 status (<i<p</i< < 0.001; AUC: 0.92), and the absence of the NEDA-4 status (<i<p</i< < 0.001; AUC: 0.839). <i<Conclusions:</i< Annual plasma NfL increases of more than 10% appear to be a useful tool for assessing disease activity in treated MS patients. multiple sclerosis disease activity neurofilament light chain neurofilament dynamics NEDA Medicine (General) Pavol Mikula verfasserin aut Zuzana Gdovinová verfasserin aut Marianna Vitková verfasserin aut Norbert Žilka verfasserin aut Jozef Hanes verfasserin aut Lýdia Frigová verfasserin aut Jarmila Szilasiová verfasserin aut In Medicina MDPI AG, 2016 59(2023), 5, p 865 (DE-627)354543296 (DE-600)2088820-X 16489144 nnns volume:59 year:2023 number:5, p 865 https://doi.org/10.3390/medicina59050865 kostenfrei https://doaj.org/article/af300faefd1541669aed63075b4289cb kostenfrei https://www.mdpi.com/1648-9144/59/5/865 kostenfrei https://doaj.org/toc/1010-660X Journal toc kostenfrei https://doaj.org/toc/1648-9144 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 59 2023 5, p 865 |
language |
English |
source |
In Medicina 59(2023), 5, p 865 volume:59 year:2023 number:5, p 865 |
sourceStr |
In Medicina 59(2023), 5, p 865 volume:59 year:2023 number:5, p 865 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
multiple sclerosis disease activity neurofilament light chain neurofilament dynamics NEDA Medicine (General) |
isfreeaccess_bool |
true |
container_title |
Medicina |
authorswithroles_txt_mv |
Miriam Fedičová @@aut@@ Pavol Mikula @@aut@@ Zuzana Gdovinová @@aut@@ Marianna Vitková @@aut@@ Norbert Žilka @@aut@@ Jozef Hanes @@aut@@ Lýdia Frigová @@aut@@ Jarmila Szilasiová @@aut@@ |
publishDateDaySort_date |
2023-01-01T00:00:00Z |
hierarchy_top_id |
354543296 |
id |
DOAJ094343918 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ094343918</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413033508.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/medicina59050865</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ094343918</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJaf300faefd1541669aed63075b4289cb</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Miriam Fedičová</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><i<Background and Objectives</i<: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of disease activity (NEDA) in a cohort of multiple sclerosis (MS) patients. <i<Materials and Methods:</i< Levels of pNfL (SIMOA) were examined in 141 MS patients and analyzed in relationship to the NEDA-3 status (absence of relapse, disability worsening, and MRI activity) and NEDA-4 (NEDA-3 extended by brain volume loss ≤ 0.4%) during the last 12 months. Patients were divided into two groups: annual pNfL change with an increase of less than 10% (group 1), and pNfL increases of more than 10% (group 2). <i<Results:</i< The mean age of the study participants (<i<n</i< = 141, 61% females) was 42.33 years (SD, 10.17), and the median disability score was 4.0 (3.5–5.0). The ROC analysis showed that a pNfL annual change ≥ 10% correlates with the absence of the NEDA-3 status (<i<p</i< < 0.001; AUC: 0.92), and the absence of the NEDA-4 status (<i<p</i< < 0.001; AUC: 0.839). <i<Conclusions:</i< Annual plasma NfL increases of more than 10% appear to be a useful tool for assessing disease activity in treated MS patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multiple sclerosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">disease activity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">neurofilament light chain</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">neurofilament dynamics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">NEDA</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pavol Mikula</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zuzana Gdovinová</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marianna Vitková</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Norbert Žilka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jozef Hanes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lýdia Frigová</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jarmila Szilasiová</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Medicina</subfield><subfield code="d">MDPI AG, 2016</subfield><subfield code="g">59(2023), 5, p 865</subfield><subfield code="w">(DE-627)354543296</subfield><subfield code="w">(DE-600)2088820-X</subfield><subfield code="x">16489144</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:59</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:5, p 865</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/medicina59050865</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/af300faefd1541669aed63075b4289cb</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1648-9144/59/5/865</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1010-660X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1648-9144</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">59</subfield><subfield code="j">2023</subfield><subfield code="e">5, p 865</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Miriam Fedičová |
spellingShingle |
Miriam Fedičová misc R5-920 misc multiple sclerosis misc disease activity misc neurofilament light chain misc neurofilament dynamics misc NEDA misc Medicine (General) Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis |
authorStr |
Miriam Fedičová |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)354543296 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
R5-920 |
illustrated |
Not Illustrated |
issn |
16489144 |
topic_title |
R5-920 Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis multiple sclerosis disease activity neurofilament light chain neurofilament dynamics NEDA |
topic |
misc R5-920 misc multiple sclerosis misc disease activity misc neurofilament light chain misc neurofilament dynamics misc NEDA misc Medicine (General) |
topic_unstemmed |
misc R5-920 misc multiple sclerosis misc disease activity misc neurofilament light chain misc neurofilament dynamics misc NEDA misc Medicine (General) |
topic_browse |
misc R5-920 misc multiple sclerosis misc disease activity misc neurofilament light chain misc neurofilament dynamics misc NEDA misc Medicine (General) |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Medicina |
hierarchy_parent_id |
354543296 |
hierarchy_top_title |
Medicina |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)354543296 (DE-600)2088820-X |
title |
Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis |
ctrlnum |
(DE-627)DOAJ094343918 (DE-599)DOAJaf300faefd1541669aed63075b4289cb |
title_full |
Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis |
author_sort |
Miriam Fedičová |
journal |
Medicina |
journalStr |
Medicina |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2023 |
contenttype_str_mv |
txt |
author_browse |
Miriam Fedičová Pavol Mikula Zuzana Gdovinová Marianna Vitková Norbert Žilka Jozef Hanes Lýdia Frigová Jarmila Szilasiová |
container_volume |
59 |
class |
R5-920 |
format_se |
Elektronische Aufsätze |
author-letter |
Miriam Fedičová |
doi_str_mv |
10.3390/medicina59050865 |
author2-role |
verfasserin |
title_sort |
annual plasma neurofilament dynamics is a sensitive biomarker of disease activity in patients with multiple sclerosis |
callnumber |
R5-920 |
title_auth |
Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis |
abstract |
<i<Background and Objectives</i<: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of disease activity (NEDA) in a cohort of multiple sclerosis (MS) patients. <i<Materials and Methods:</i< Levels of pNfL (SIMOA) were examined in 141 MS patients and analyzed in relationship to the NEDA-3 status (absence of relapse, disability worsening, and MRI activity) and NEDA-4 (NEDA-3 extended by brain volume loss ≤ 0.4%) during the last 12 months. Patients were divided into two groups: annual pNfL change with an increase of less than 10% (group 1), and pNfL increases of more than 10% (group 2). <i<Results:</i< The mean age of the study participants (<i<n</i< = 141, 61% females) was 42.33 years (SD, 10.17), and the median disability score was 4.0 (3.5–5.0). The ROC analysis showed that a pNfL annual change ≥ 10% correlates with the absence of the NEDA-3 status (<i<p</i< < 0.001; AUC: 0.92), and the absence of the NEDA-4 status (<i<p</i< < 0.001; AUC: 0.839). <i<Conclusions:</i< Annual plasma NfL increases of more than 10% appear to be a useful tool for assessing disease activity in treated MS patients. |
abstractGer |
<i<Background and Objectives</i<: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of disease activity (NEDA) in a cohort of multiple sclerosis (MS) patients. <i<Materials and Methods:</i< Levels of pNfL (SIMOA) were examined in 141 MS patients and analyzed in relationship to the NEDA-3 status (absence of relapse, disability worsening, and MRI activity) and NEDA-4 (NEDA-3 extended by brain volume loss ≤ 0.4%) during the last 12 months. Patients were divided into two groups: annual pNfL change with an increase of less than 10% (group 1), and pNfL increases of more than 10% (group 2). <i<Results:</i< The mean age of the study participants (<i<n</i< = 141, 61% females) was 42.33 years (SD, 10.17), and the median disability score was 4.0 (3.5–5.0). The ROC analysis showed that a pNfL annual change ≥ 10% correlates with the absence of the NEDA-3 status (<i<p</i< < 0.001; AUC: 0.92), and the absence of the NEDA-4 status (<i<p</i< < 0.001; AUC: 0.839). <i<Conclusions:</i< Annual plasma NfL increases of more than 10% appear to be a useful tool for assessing disease activity in treated MS patients. |
abstract_unstemmed |
<i<Background and Objectives</i<: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of disease activity (NEDA) in a cohort of multiple sclerosis (MS) patients. <i<Materials and Methods:</i< Levels of pNfL (SIMOA) were examined in 141 MS patients and analyzed in relationship to the NEDA-3 status (absence of relapse, disability worsening, and MRI activity) and NEDA-4 (NEDA-3 extended by brain volume loss ≤ 0.4%) during the last 12 months. Patients were divided into two groups: annual pNfL change with an increase of less than 10% (group 1), and pNfL increases of more than 10% (group 2). <i<Results:</i< The mean age of the study participants (<i<n</i< = 141, 61% females) was 42.33 years (SD, 10.17), and the median disability score was 4.0 (3.5–5.0). The ROC analysis showed that a pNfL annual change ≥ 10% correlates with the absence of the NEDA-3 status (<i<p</i< < 0.001; AUC: 0.92), and the absence of the NEDA-4 status (<i<p</i< < 0.001; AUC: 0.839). <i<Conclusions:</i< Annual plasma NfL increases of more than 10% appear to be a useful tool for assessing disease activity in treated MS patients. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
5, p 865 |
title_short |
Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis |
url |
https://doi.org/10.3390/medicina59050865 https://doaj.org/article/af300faefd1541669aed63075b4289cb https://www.mdpi.com/1648-9144/59/5/865 https://doaj.org/toc/1010-660X https://doaj.org/toc/1648-9144 |
remote_bool |
true |
author2 |
Pavol Mikula Zuzana Gdovinová Marianna Vitková Norbert Žilka Jozef Hanes Lýdia Frigová Jarmila Szilasiová |
author2Str |
Pavol Mikula Zuzana Gdovinová Marianna Vitková Norbert Žilka Jozef Hanes Lýdia Frigová Jarmila Szilasiová |
ppnlink |
354543296 |
callnumber-subject |
R - General Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3390/medicina59050865 |
callnumber-a |
R5-920 |
up_date |
2024-07-03T22:38:33.399Z |
_version_ |
1803599283120766976 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ094343918</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413033508.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/medicina59050865</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ094343918</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJaf300faefd1541669aed63075b4289cb</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Miriam Fedičová</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><i<Background and Objectives</i<: Neurofilament light chain (NfL) is a sensitive biomarker of neuroaxonal damage. This study aimed to assess the relationship between the annual change in plasma NfL (pNfL) and disease activity in the past year, as defined by the concept no evidence of disease activity (NEDA) in a cohort of multiple sclerosis (MS) patients. <i<Materials and Methods:</i< Levels of pNfL (SIMOA) were examined in 141 MS patients and analyzed in relationship to the NEDA-3 status (absence of relapse, disability worsening, and MRI activity) and NEDA-4 (NEDA-3 extended by brain volume loss ≤ 0.4%) during the last 12 months. Patients were divided into two groups: annual pNfL change with an increase of less than 10% (group 1), and pNfL increases of more than 10% (group 2). <i<Results:</i< The mean age of the study participants (<i<n</i< = 141, 61% females) was 42.33 years (SD, 10.17), and the median disability score was 4.0 (3.5–5.0). The ROC analysis showed that a pNfL annual change ≥ 10% correlates with the absence of the NEDA-3 status (<i<p</i< < 0.001; AUC: 0.92), and the absence of the NEDA-4 status (<i<p</i< < 0.001; AUC: 0.839). <i<Conclusions:</i< Annual plasma NfL increases of more than 10% appear to be a useful tool for assessing disease activity in treated MS patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multiple sclerosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">disease activity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">neurofilament light chain</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">neurofilament dynamics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">NEDA</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pavol Mikula</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zuzana Gdovinová</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marianna Vitková</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Norbert Žilka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jozef Hanes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lýdia Frigová</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jarmila Szilasiová</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Medicina</subfield><subfield code="d">MDPI AG, 2016</subfield><subfield code="g">59(2023), 5, p 865</subfield><subfield code="w">(DE-627)354543296</subfield><subfield code="w">(DE-600)2088820-X</subfield><subfield code="x">16489144</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:59</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:5, p 865</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/medicina59050865</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/af300faefd1541669aed63075b4289cb</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1648-9144/59/5/865</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1010-660X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1648-9144</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">59</subfield><subfield code="j">2023</subfield><subfield code="e">5, p 865</subfield></datafield></record></collection>
|
score |
7.3999414 |